Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Naive HBI0101 CAR-T

Phase 1Cell therapy

HHadassah Medical Organization

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory Multiple Myeloma (MM)Recruiting

Relapsed/refractory Multiple Myeloma (MM)Phase 1

Recruiting

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Relapsed/refractory Multiple Myeloma (MM)

NCT07333430

Clinical

Trials by Indication[1]

Relapsed/Refractory Multiple Myeloma (MM)1 trial

A Phase 1a/1b Open-Label Study With Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting·HHadassah Medical Organization·Phase 1·NCT07333430·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Naive HBI0101 CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naive HBI0101 CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naive HBI0101 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hadassah Medical Organization company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: HHadassah Medical Organization

Related News